Browse News
Filter News
Found 17 articles
-
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
8/3/2023
Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported operational highlights and financial results for the second quarter ended June 30, 2023.
-
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
5/4/2023
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.
-
In an earnings call Wednesday, bluebird bio revealed it is unlikely to meet its first-quarter goal to submit a Biologics License Application for sickle cell disease (SCD) gene therapy lovo-cel.
-
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
2/23/2023
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2022.
-
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
1/5/2023
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced its strategic priorities for the upcoming two years as the Company enters its next phase of pipeline execution and platform innovation.
-
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/3/2022
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2022.
-
Regeneron Reports Third Quarter 2022 Financial and Operating Results
11/3/2022
Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2022 and provided a business update.
-
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
8/4/2022
Intellia Therapeutics, Inc. today reported operational highlights and financial results for the second quarter ended June 30, 2022.
-
Intellia’s first-quarter financial conference call and report focused on the ongoing Phase I trial of NTLA-2001 in transthyretin (ATTR) amyloidosis with polyneuropathy patients.
-
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
5/5/2022
Intellia Therapeutics, Inc. today reported operational highlights and financial results for the first quarter ended March 31, 2022.
-
Regeneron Reports First Quarter 2022 Financial and Operating Results
5/4/2022
Regeneron Pharmaceuticals, Inc. announced financial results for the first quarter of 2022 and provided a business update.
-
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
2/24/2022
Intellia Therapeutics, Inc., a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported operational highlights and financial results for the fourth quarter and year ended December 31, 2021.
-
Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
2/4/2022
Fourth quarter 2021 revenues increased 104% to $4.95 billion versus fourth quarter 2020 including $2.30 billion attributable to REGEN-COV.
-
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022
1/6/2022
Intellia Therapeutics, Inc. today outlined its expected milestones and the following strategic priorities for 2022.
-
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
11/4/2021
Intellia Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021, and recent operational highlights.
-
Regeneron Reports Second Quarter 2021 Financial and Operating Results
8/5/2021
Regeneron Pharmaceuticals, Inc. announced financial results for the second quarter of 2021 and provided a business update.
-
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
8/5/2021
Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported financial results for the second quarter ended June 30, 2021, and recent operational highlights.